At the news
? NEUTRALIMPACT 3/10 425 filed Nov 2, 2026 at 16:03 ET
TCGX Acquisition Corp. and TriGemX Bio announced the confidential submission of a draft S-4 registration statement to the SEC, a procedural milestone toward completing their previously announced business combination. The deal is expected to close in Q1 2027, subject to shareholder approval, SEC effectiveness, and Nasdaq listing. No new material terms or changes to the deal structure were disclosed.
- TriGemX Bio and TCGX Acquisition Corp. confidentially submitted a draft registration statement on Form S-4 to the SEC on November 2, 2026.
- The business combination is expected to close in Q1 2027, subject to TCGX shareholder approval, SEC effectiveness, Nasdaq listing, and other customary conditions.
- The combined company will be named TriGemX Bio, Inc. and trade on Nasdaq under the ticker TGEM.
- Elismetrep, TriGemX Bio's migraine drug candidate, is in Phase 3 trials with first results expected in mid-2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access